



(51) International Patent Classification:

A61K 9/56 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4458 (2006.01) *C07D 211/34* (2006.01)
A61K 9/16 (2006.01)

(21) International Application Number:

PCT/CA2015/051109

(22) International Filing Date:

30 October 2015 (30.10.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/122,847 31 October 2014 (31.10.2014) US
 2,902,911 27 August 2015 (27.08.2015) CA

(71) Applicant: **PURDUE PHARMA** [CA/CA]; 575 Granite Court, Pickering, Ontario L1W 3W8 (CA).

(72) Inventors: **VARGAS RINCON, Ricardo Alberto**; 6602 Harmony Hill, Mississauga, Ontario L5W 1S4 (CA).
REIZ, Joseph Leonard; 44 Wrenwood Court, Markham, Ontario L3R 6H4 (CA).

(74) Agents: **GOWLING WLG (CANADA) LLP** et al.; 1 First Canadian Place, 100 King Street West, Suite 1600, Toronto, Ontario M5X 1G5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: METHODS AND COMPOSITIONS PARTICULARLY FOR TREATMENT OF ATTENTION DEFICIT DISORDER

Figure 7: Results of PK Study 063-007 (Formulation I 100 mg vs Ritalin 60 mg)



(57) Abstract: There is described, inter alia, a coated bead comprising: (a) a granule; (b) a first layer coated over the granule, the first layer comprising a first amount of an active pharmaceutical ingredient comprising a central nervous system stimulant; and (c) a second layer coated over the first layer, the second layer being present in an amount sufficient to substantially delay release of the active pharmaceutical ingredient in the first layer until after the coated bead reaches a distal intestine portion of a subject to whom the coated bead is administered; and (d) the third layer coated over the second layer, the third layer comprising a second amount of the active pharmaceutical ingredient, the third layer being configured to permit substantially immediate release of the active pharmaceutical ingredient comprised therein. Embodiments related to a solid oral pharmaceutical composition are also described.